|
21 |
Laboratory parameters related to disease severity and physical performance after reconvalescence of acute COVID-19 infection
Enthalten in Scientific reports Bd. 14, 6.5.2024, Nr. 1, date:12.2024: 1-10
|
|
|
|
22 |
Leitlinie S1: Long COVID: Differenzialdiagnostik und Behandlungsstrategien
Enthalten in Wiener klinische Wochenschrift Bd. 133, 1.12.2021, Nr. 7, date:12.2021: 237-278
|
|
|
|
23 |
Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients’ performance: a prospective observational cohort study
Enthalten in Respiratory research Bd. 21, 21.10.2020, Nr. 1, date:12.2020: 1-9
|
|
|
|
24 |
Pulmonary recovery from COVID-19 in patients with metabolic diseases: a longitudinal prospective cohort study
Enthalten in Scientific reports Bd. 13, 14.2.2023, Nr. 1, date:12.2023: 1-12
|
|
|
|
25 |
Risk assessment in precapillary pulmonary hypertension: a comparative analysis
Enthalten in Respiratory research Bd. 22, 21.1.2021, Nr. 1, date:12.2021: 1-12
|
|
|
|
26 |
Severe COVID-19 disease is associated with genetic factors affecting plasma ACE2 receptor and CRP concentrations
Enthalten in Scientific reports Bd. 15, 8.2.2025, Nr. 1, date:12.2025: 1-12
|
|
|
|
27 |
The combination of supervised and unsupervised learning based risk stratification and phenotyping in pulmonary arterial hypertension—a long-term retrospective multicenter trial
Enthalten in BMC pulmonary medicine Bd. 23, 25.4.2023, Nr. 1, date:12.2023: 1-12
|
|
Administration
